Your browser doesn't support javascript.
Securing Wider EU Commitment to the Elimination of HCV.
Wedemeyer, Heiner; Tergast, Tammo L; Lazarus, Jeffrey V; Razavi, Homie; Bakoyannis, Kostas; Baptista-Leite, Ricardo; Bartoli, Marco; Bruggmann, Philip; Busoi, Cristian-Silviu; Buti, Maria; Carballo, Manuel; Castera, Laurent; Colombo, Massimo; Coutinho, Rodrigo Sousa; Dadon, Yuval; Esmat, Gamal; Esteban, Rafael; Colom Farran, Joan; Gillyon-Powell, Mark; Goldberg, David; Hutchinson, Sharon; Janssen, Harry L A; Kalamitsis, George; Kondili, Loreta A; Lambert, John S; Marinho, Rui Tato; Maticic, Mojca; Patricello, Aldo; Peck-Radosavljevic, Markus; Pol, Stanislas; Poljak, Mario; Pop, Cora; Sokol, Tomislov; Sypsa, Vana; Tözün, Nurdan; Younossi, Zobair; Aghemo, Alessio; Papatheodoridis, George V; Hatzakis, Angelos.
  • Wedemeyer H; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Tergast TL; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Lazarus JV; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Razavi H; Center for Disease Analysis Foundation, Lafayette, Colorado, USA.
  • Bakoyannis K; Mayor of Athens, Mayor's office, City of Athens, Greece.
  • Baptista-Leite R; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
  • Bartoli M; Institute of Health Sciences, Católica University of Portugal, Lisbon, Portugal.
  • Bruggmann P; EpaC Onlus, Italy.
  • Busoi CS; Arud Centre for Addiction Medicine, Zurich, Switzerland.
  • Buti M; European Parliament, Brussels, Belgium.
  • Carballo M; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III. Barcelona, Spain.
  • Castera L; International Centre for Migration, Health and Development, Geneva, Switzerland.
  • Colombo M; Department of Hepatology, Hôpital Beaujon AP-HP- University of Paris-VII, Clichy, France.
  • Coutinho RS; Liver Centre, San Raffaele Hospital, Milan, Italy.
  • Dadon Y; Ares do Pinhal, Non-Governmental Organization for Social Inclusion, Lisbon, Portugal.
  • Esmat G; Ministry of Health, Israel.
  • Esteban R; Endemic Medicine and Department,of HepatoGastroenterology Faculty of Medicine, Cairo University Hospital, Cairo, Egypt.
  • Colom Farran J; Liver Unit, Hospital Universitari Vall d'Hebron and CIBERHED del Instituto Carlos III. Barcelona, Spain.
  • Gillyon-Powell M; Public Health Agency of Catalonia, Barcelona, Spain.
  • Goldberg D; NHS England and NHS Improvement, UK.
  • Hutchinson S; Public Health, Scotland.
  • Janssen HLA; School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, UK.
  • Kalamitsis G; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands.
  • Kondili LA; Liver Patients' International, Brussels, Belgium.
  • Lambert JS; Istituto Superiore di Sanità, Rome, Italy.
  • Marinho RT; Mater Misericordiae University Hospital, and UCD School of Medicine, Dublin, Ireland.
  • Maticic M; Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisboa, Portugal.
  • Patricello A; Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, Slovenia.
  • Peck-Radosavljevic M; Faculty of Medicine, University of Ljubljana, Solvenia.
  • Pol S; European Parliament, Brussels, Belgium.
  • Poljak M; Department of Internal Medicine & Gastroenterology (IMuG) Hepatology, Endocrinology, Rheumatology and Nephrology with Centralized Emergency Department (ZAE), Klagenfurt, Austria.
  • Pop C; Department of Hepatology, Université de Paris, APHP, Hopital Cochin, Paris, France.
  • Sokol T; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Sypsa V; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Tözün N; European Parliament, Brussels, Belgium.
  • Younossi Z; Epidemiology and Preventive Medicine, National and Kapodistrian University of Athens Medical School, Athens, Greece.
  • Aghemo A; Department of Gastroenterology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
  • Papatheodoridis GV; Department of Medicine, Inova Health Fairfax Medical Campus, Falls Church, Virginia, USA.
  • Hatzakis A; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy.
Liver Int ; 2022 Oct 05.
Article in English | MEDLINE | ID: covidwho-2236898
ABSTRACT
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programs - from the municipality level to the EU level - were launched, resulting in an overall decrease of viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the 3rd EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and report the 'Call-to-Action' statement supported by all the major relevant European associations in the field.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Liv.15446

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Liv.15446